Objective  To evaluate the efficacy, safety and economics of dulaglutide in the treatment of type 2 diabetes mellitus (T2DM) by rapid health technology assessment, and to provide the evidence-based medical evidence to clinic.

Methods  PubMed, Embase, The Cochrane Library, CNKI, WanFang Data, VIP and the related health technology assessment (HTA) websites and databases were electronically searched to collect high-quality clinical evidence and pharmacoeconomics evaluation literature of dulaglutide in the treatment of T2DM from their inception dates to March 31st, 2023. Two reviewers independently screened literature, extracted data, accessed the quality of included studies and qualitatively described and analyzed the results.

Results  A total of 22 studies were included, including 1 HTA report, 13 systematic review/Meta-analyses and 8 pharmacoeconomics researches. The result of efficacy showed that dulaglutide could lower the level of HbA1c and fasting blood glucose, and improve the success rate of HbA1c in patients with T2DM, had a better impact on body weight than sulfonylureas and insulin. In terms of safety, the risk of hypoglycemia and pancreatitis caused by dulaglutide was low, but the incidence of gastrointestinal adverse reactions was significantly increased, it could reduce the incidence of cardiovascular adverse events and strokes, and had no cardiovascular or cerebrovascular adverse effects. The economic evaluation results showed that dulaglutide was a cost-effective treatment, but the research of cost-effectiveness analysis of dulaglutide was limited in China.

Conclusion  Dulaglutide has been shown to be effective and safe in the treatment of T2DM. It’s necessary to carry out the economics research of dulaglutide in China.

1.Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948959. DOI: 10.1001/jama.2013.168118.

2.Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J]. JAMA, 2017, 317(24): 2515-2523. DOI: 10.1001/jama.2017.7596.

3.Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020, 369: m997. DOI: 10.1136/bmj.m997.

4.中国医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.

5.唐惠林, 门鹏, 翟所迪. 药物快速卫生技术评估方法及应用[J].临床药物治疗杂志, 2016, 14(2): 1-4. [Tang HL, Men P, Zhai SD. Introducing and exploring the method of rapid review on drugs[J]. Clinical Medication Journal, 2016, 14(2): 1-4.] DOI: 10.3969/j.issn.1672-3384.2016.02.001.

6.Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both[J]. BMJ, 2017, 358: j4008. DOI: 10.1136/bmj.j4008.

7.INAHTA. INAHTA HTA Checklist English[EB/OL]. (2007-05) [2022-01-10]. http://www.Inata.org/wp-content/up-loads/2014/04/INAHTA-HTA-Checklist-English.pdf.

8.Husereau D, Drummond M, Petrous S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force[J]. Value Health, 2013, 16(2): 231-250. DOI: 10.1016/j.jval.2013.02.002.

9.Institute for Quality and Efficiency in Health Care. Dulaglutide - benefit assessment according to § 35a SGB V[R]. Germany: Institute for Quality and Efficiency in Health Care, 2015: 1-150.

10.Xu J, Yao D, Xia J, et al. Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: a systematic review and meta-analysis[J]. J Clin Pharm Ther, 2021, 46(5): 1245-1253. DOI: 10.1111/jcpt.13398.

11.Zhang L, Zhang M, Zhang Y, et al. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review[J]. Sci Rep, 2016, 6: 18904. DOI: 10.1038/srep18904.

12.Qie S, Li X, Wang X, et al. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials[J]. Endocrine, 2020, 68(3): 508-517. DOI: 10.1007/s12020-020-02193-9.

13.Morieri ML, Rigato M, Frison V, et al. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly: a real-world study and meta-analysis of observational studies[J]. Metabolism, 2020, 106: 154190. DOI: 10.1016/j.metabol.2020.154190.

14.Chang KC, Shao SC, Kuo S, et al. Comparative efectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis[J]. Cardiovasc Diabetol, 2020, 19(1): 172. DOI: 10.1186/s12933-020-01148-8.

15.Karagiannis T, Liakos A, Bekiari E, et al. Efficacy and safety of once-weekly glucagon-like peptide 1receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials[J]. Diabetes Obes Metab, 2015, 17(11): 1065-1074. DOI: 10.1111/dom.12541.

16.Singh S, Wright EE Jr, Kwan AY, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis[J]. Diabetes Obes Metab, 2017, 19(2): 228-238. DOI: 10.1111/dom.12805.

17.Ferdinand KC, Botros FT, Atisso CM, et al. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events[J]. Cardiovasc Diabetol, 2016, 15: 38. DOI: 10.1186/s12933-016-0355-z.

18.Yu B, Lin F, Wang M, et al. Efcacy and safety of dulaglutide compared with the frstline hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and metaanalysis[J]. Sci Rep, 2022, 12(1): 18281. DOI: 10.1038/s41598-022-22263-4.

19.Jiang Y, Liu J, Chen X, et al. Efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus: a network meta-analysis[J]. Adv Ther, 2021, 38(3): 1470-1482. DOI: 10.1007/s12325-021-01637-6.

20.Zaccardi F, Htike ZZ, Webb DR, et al. Benefifits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis[J]. Ann Intern Med, 2016, 164(2): 102-113. DOI: 10.7326/M15-1432.

21.Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis[J]. Ann Intern Med, 2020, 173(4): 278-286. DOI: 10.7326/M20-0864.

22.Alfayez OM, Almohammed OA, Alkhezi OS, et al. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis[J]. Cardiovasc Diabetol, 2020, 19(1): 96. DOI: 10.1186/s12933-020-01070-z.

23.Basson M, Ntais D, Ayyub R, et al. The cost-effectiveness of dulaglutide 1.5 mg versus exenatide qw for the treatment of patients with type 2 diabetes mellitus in France[J]. Diabetes Ther, 2018, 9(1): 13-25. DOI: 10.1007/s13300-017-0321-0.

24.Ishii H, Madin-Warburton M, Strizek A, et al. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan[J]. J Med Econ, 2018, 21(5): 488-496. DOI: 10.1080/13696998.2018.1431918.  

25.Dilla T, Alexiou D, Chatzitheofilou I, et al. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI≥30 kg/m2[J]. J Med Econ, 2017, 20(5): 443-452. DOI: 10.1080/13696998.2016.1275651.

26.Lasalvia P, Baquero L, Otálora-Esteban M, et al. Cost-effectiveness of dulaglutide compared with liraglutide and glargine in type 2 diabetes mellitus patients in Colombia[J]. Value Health Reg Issues, 2017, 14: 35-40. DOI: 10.1016/j.vhri.2016.10.006.

27.Pollock RF, Norrbacka K, Cameron C, et al. A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for type 2 diabetes in Canada[J]. J Comp Eff Res, 2019, 8(4): 229-240. DOI: 10.2217/cer-2018-0073.

28.Hu S, Wang S, Qi C, et al. Cost-utility analysis of once-weekly semaglutide, dulaglutide, and exenatide for type 2 diabetes patients receiving metformin-based background therapy in China[J]. Front Pharmacol, 2022, 13: 831364. DOI: 10.3389/fphar.2022.831364.

29.Su Y, Zhang S, Wu Z, et al. Pharmacoeconomic analysis (CER) of Dulaglutide and Liraglutide in the treatment of patients with type 2 diabetes[J]. Front Endocrinol (Lausanne), 2023, 14: 1054946. DOI: 10.3389/fendo.2023.1054946.

30.Ekhlasi M, Taheri S, Yousefi N. Cost-effectiveness of dulaglutide versus liraglutide for management of type 2 diabetes mellitus in Iran[J]. Value Health Reg Issues, 2022, 32: 54-61. DOI: 10.1016/j.vhri.2022.07.005.

31.纪汶君, 门鹏, 李娜. 度拉糖肽治疗 2 型糖尿病快速卫生技术评估[J]. 中国药业, 2023, 32(6): 109-115. [Ji WJ, Men P, Li N, et al. Dulaglutide in the treatment of type 2 diabetes mellitus: a rapid health technology assessment[J]. China Pharmaceuticals, 2023, 32(6): 109-115.] DOI: 10.3969/j.issn.1006-4931.2023.06.028.

32.王军, 王小钦. 正确认识和提高Meta分析的质量[J]. 华南国防医学杂志, 2013, 27(11): 824-825. [Wang J, Wang XQ. Correct recognition and quality improvement of meta analysis[J]. Military Medical Journal of South China, 2013, 27(11): 824-825.] DOI: CNKI:SUN:HNGY.0.2013-11-018.

33.杜茂林, 王福彦, 主编. 医学统计学[M]. 北京: 人民军医出版社, 2015: 190-191.